Related Experiment Videos
Galacto-oligosaccharides relieve constipation in elderly people
1Valio Ltd, R&D Centre, Department of Pharmacology and Toxicology, University of Helsinki, Finland. ulla.teuri@valio.fi
Annals of Nutrition & Metabolism
|January 23, 1999
Summary
Galacto-oligosaccharides (GOS) in yogurt increased bowel movement frequency in elderly individuals experiencing constipation. While not statistically significant for all measures, GOS showed a trend toward improving defecation ease.
Area of Science:
- Gerontology
- Gastroenterology
- Nutritional Science
Background:
- Constipation is a common issue in the elderly population, impacting quality of life.
- Dietary interventions, including prebiotics, are explored for managing constipation.
- Galacto-oligosaccharides (GOS) are recognized prebiotics with potential laxative effects.
Purpose of the Study:
- To evaluate the efficacy of galacto-oligosaccharides (GOS) in alleviating constipation among elderly individuals.
- To assess the impact of GOS supplementation on defecation frequency, stool consistency, and ease of defecation.
Main Methods:
- A double-blind, two-period cross-over study involving 14 elderly female subjects with constipation.
- Subjects consumed either control yogurts or yogurts containing 9g of GOS daily for two weeks per period.
- Bowel function was monitored daily via questionnaires, with laxative use recorded.
Main Results:
- Defecation frequency was significantly higher during the GOS period (7.1/week) compared to the control period (5.9/week).
- GOS did not show a statistically significant effect on laxative use or stool consistency.
- A trend suggested GOS may ease defecation (p=0.07), with similar adverse gastrointestinal symptoms across both groups.
Conclusions:
- Galacto-oligosaccharides (GOS) appear to offer relief from constipation in the elderly, though individual responses vary.
- Daily GOS supplementation via yogurt may be a viable option for improving bowel regularity in older adults.
- Further research could explore optimal GOS dosages and long-term effects in geriatric populations.